Is clinical treatment the gold standard in the treatment of acute type B aortic dissections?
The type B aortic dissection treatment is showing a paradigm change with the consolidation of the endovascular treatment. Duarte et al.
[1] present a review of the most important works that demonstrate this evolution. The concept that the type B aortic dissection treatment is primarily clinical, with surgery reserved for complicated cases, are based on the first publications of IRAD [2] , in 20001. This work showed hospital mortality of 10% for clinically treated cases. The surgical treatment presented mortality rate of 31% with 18% of paraplegia. These results were not obtained by randomized controlled trials, nor considered the technical innovations of the elephant's trunk and cerebral anterograde perfusion. However, the patients initially treated medically, showed 20 to 50% of mortality [3] in late evolution, providing the search for new treatments. The INSTEAD TRIAL [4] was the first randomized multicenter study comparing the optimized medical treatment with endovascular treatment in uncomplicated type B aortic
